Antibody–drug conjugates (ADCs) comprised of a desirable monoclonal antibody, an active
cytotoxic drug and an appropriate linker are considered to be an innovative therapeutic …

Enfortumab vedotin is a first-in-class Nectin-4-directed antibody-drug conjugate approved by
the US Food and Drug Administration for the treatment of patients with locally advanced or …

PURPOSE Locally advanced or metastatic urothelial carcinoma is an incurable disease with
limited treatment options, especially for patients who were previously treated with platinum …

Abstract NECTIN-4 [a poliovirus receptor-related-4 (pvrl-4) encoded protein] is a Ca 2+
independent immunoglobulin-like protein. Along with other Nectins (Nectin-1,-2 and-3), it is …

The Nectin cell adhesion molecule (Nectin) family members are Ca 2+‑independent
immunoglobulin‑like cellular adhesion molecules (including Nectins 1‑4), involved in cell …

Background Triple-negative breast cancers (TNBCs) are associated with a poor prognosis.
In contrast to other molecular subtypes, they have no identified specific target and …

The Nectin cell adhesion protein 4 (Nectin-4) is overexpressed in multiple human
malignancies. Such aberrant expression is correlated with cancer progression and poor …

Antibody–drug conjugates (ADCs) constitute a relatively new group of anticancer agents,
whose first appearance took place about two decades ago, but a renewed interest occurred …

Frizzled receptors mediate Wnt ligand signalling, which is crucially involved in regulating
tissue development and differentiation, and is often deregulated in cancer. In this study, we …

Abstract Background Nectin-4 and Trop-2 are transmembrane targets of FDA-approved
antibody-drug conjugates (ADC) Enfortumab-vedotin (EV) and Sacituzumab govitecan (SG) …